Director/PDMR Shareholding
Summary by AI BETAClose X
25 September 2025
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that it was notified on 25 September 2025 that Karen Knudsen, Non-Executive Director, had acquired 9 American Depositary Shares (ADSs) in the Company on 9 September 2025, pursuant to the reinvestment of the first interim dividend in respect of the year ending 31 December 2025, paid by the Company on 8 September 2025. Two ADSs are equivalent to one of the Company's ordinary shares of $0.25 each.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Karen Knudsen |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-Executive Director |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
AstraZeneca PLC |
||||
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 0463531089
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of AstraZeneca PLC American Depositary Shares through the reinvestment of the first interim dividend of the Company, in respect of the year ending 31 December 2025, paid by the Company on 8 September 2025. |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
9 September 2025 |
||||
|
f)
|
Place of the transaction
|
XNAS |
||||
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 23 minutes ago River Global Plc
- 1 hour ago Pipehawk
- 1 hour ago Frasers Group
- 1 hour ago DP Aircraft I Limited Pref
- 1 hour ago Cropper (James)